Impact of Clinical Practice Guidelines on the Clinical Microbiology Laboratory When Using Automated Blood Culture Systems for Bacterial Contamination Screening of Apheresis Platelet Products

Les C. Stutzman,Nadine Sullivan
DOI: https://doi.org/10.1128/JCM.42.12.5963-5964.2004
2004-12-01
Journal of Clinical Microbiology
Abstract:We are writing to clarify what we believe is an inaccuracy, perhaps due to some misunderstanding, found in Peter Gilligan's April 2004 minireview (2). To be specific, we reference statements made by the author on page 1394 under the subheading “Platelet contamination.” Paragraph two under that subheading contains sentences in which the author refers to TREK Diagnostic Systems, Inc., of Westlake (Cleveland), Ohio, as facing the imposition by BioMerieux of restrictions to the marketing of its technology for bacterial contamination testing of platelets similar to those Becton Dickinson faces. We wish to inform the readers of your journal that TREK Diagnostic Systems, Inc., has no “similar” agreement restriction as stated in Gilligan's review. Users of TREK's ESP and VersaTREK technology are able to use these technologies in accordance with the American Association of Blood Banks (AABB) Standards for Blood Banks and Transfusion Services guidelines (edition 22) (1) for validation and routine use of bacterial contamination testing of platelet products via an automated culture system. TREK Diagnostic Systems, Inc., has an agreement that expressly protects “TREK, its Distributors, and End Users” from suit for TREK to market the ESP (and VersaTREK) technology worldwide for human diagnostic testing and related testing of sterile body fluids. The March 2004 AABB Standards for Blood Banks and Transfusion Services, edition 22 (1), reminds facilities that “QC monitoring of bacteria detection may not be used for product labeling even if an FDA-cleared method is used.” Additionally, under the heading “Validation Techniques” (1), the standard states that “any technique—whether it is an FDA-approved technique used according to the manufacturer's directions or a technique that uses equipment and reagents outside intended or approved applications—requires validation to ensure that the performance of the technique is as expected. The validation plan for the procedure should be developed by each facility or laboratory, but some suggestions are offered here.” The document then proceeds to provide examples of acceptable validation protocols for various techniques, including staining, dipstick detection, spiking studies, etc.
Medicine
What problem does this paper attempt to address?